Crawford, George ESchool of Medicine |
![]() |
Dr. Crawford has over 20 years of Infectious Disease experience, with special interest in travel medicine, vaccine prevention, and nosocomial infections. He is a Master of the American College of Physicians, and a Laureate of the Texas ACP and a Laureate of the Air Force Region, Past President of the Air Force Region and Board Certified in Infectious Disease and Internal Medicine. |
7/2013 - Present | Associate Program Director | UTHSCSA, Medicine, San Antonio, TX |
1/1997 - Present | Professor | University of Texas Health Science Center at San Antonio, Medicine, San Antonio, TX |
Year | Degree | Discipline | Institution |
1972 | MD | Medicine (Highest Honors) | Northwestern University Medical School Chicago , IL |
1968 | BS | Chemistry (Magna Cum Laude) | University of Notre Dame Notre Dame , IN |
Residency | Internal Medicine | Massachusetts General Hospital Boston , MA |
|
Internship | Internal Medicine | Massachusetts General Hospital Boston , MA |
|
Postdoctoral Fellowship | Infectious Disease | University of Washington Seattle , WA |
Infectious Disease- 30 years clinical experience, vaccine trial, primary interest non-HIV infections. |
Journal Article |
Aslam MI, Cardile A, Crawford GE. Use of the Peptide Thrombopoetin Receptor Agonist Romiplostim (Nplate) in a Case of Primary HIV-Associated Thrombocytopenia Journal of the International Association of Providers of AIDS Care 2014 Feb;13(1). |
Morrison VA, et al. Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster Journal of Infectious Diseases 2013 Aug;208(4):559-563. |
Morrison V, Oxman M, Levin M, Schmader K, Guatelli J, Belts R, Gelb L, Pachucki C, Keay S, Menzies B, Griffin M, Kauffman C, Marques A, Toney J, Simberkoff M, Serrao R, Arbeit R, Gnann J, Greenberg R, Keitel W, Yeh S, Davis L, Crawford GE, Neuzil K, Johnson G, Zhang J, Harbecke R, Chan I, Keller P, Williams H, Boardman K, Silber J, Annunziato P. Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster Journal of Infectious Diseases 2013 Aug;208(4). |
Private |
|
Funding Agency | Merck/NIH |
Title | Shingles Prevention Trial |
Status | Active |
Period | 11/1998 - Present |
Role | Principal Investigator |
Grant Detail | Enrolled 1350 subjects in a double blind placebo controlled trial of a varicella vaccine and followed them for up to five years, demonstrating safety and efficacy in preventing shingles. We are now preparing to immunized those who recieved placebo. |